Michael DesJardin
Technik-/Wissenschafts-/F&E-Leiter bei HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profil
Derzeit bekleidet Michael A. DesJardin die Position des Executive VP-Technical Operations & Quality bei Horizon Therapeutics Plc und des Senior Vice President-Technical Operations bei Horizon Pharmaceutical LLC (einer Tochtergesellschaft von Horizon Therapeutics Plc). Er ist außerdem Senior Vice President-Technical Operations bei Horizon Pharmaceutical LLC. Zuvor hatte er die Position des Senior Vice President-Produktentwicklung bei Jazz Pharmaceuticals Plc und Executive Director-Implant Research & Development bei ALZA Corp. inne. Herr DesJardin erwarb einen Bachelor-Abschluss an der University of California, Berkeley.
Aktive Positionen von Michael DesJardin
| Unternehmen | Position | Beginn |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2017 |
Ehemalige bekannte Positionen von Michael DesJardin
| Unternehmen | Position | Ende |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2016 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01.03.2015 |
| ALZA CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michael DesJardin
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
